Remimazolam
Remimazolam is an ultra-short-acting benzodiazepine sedative that enhances GABA-A receptor-mediated inhibitory neurotransmission to produce dose-dependent sedation and anxiolysis, and is rapidly hydrolyzed by tissue esterases to an inactive metabolite, providing predictable and titratable sedation with rapid recovery. It is approved for procedural sedation and induction and maintenance of general anesthesia.
Molekularmasse
439,3000 g/mol
LogP
3,40
TPSA
69,40 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Pharmacokinetics (PK)
Pharmacodynamics (PD)
2D-Struktur
Cite this structure
Embed this structure
SMILES
COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21
InChI
InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1
Molecular Formula
C21H19BrN4O2
HBD / HBA
- / 5
Rotierbare Bindungen
5
Schwere Atome
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Remimazolam is an ultra-short-acting benzodiazepine sedative that enhances GABA-A receptor-mediated inhibitory neurotransmission to produce dose-dependent sedation and anxiolysis, and is rapidly hydrolyzed by tissue esterases to an inactive metabolite, providing predictable and titratable sedation with rapid recovery. It is approved for procedural sedation and induction and maintenance of general anesthesia.
Yes, Remimazolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297526. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9867812. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="remimazolam"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/remimazolam/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/remimazolam/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/remimazolam/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="remimazolam"></drugfyi-drug>